Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T17:56:14.865Z.
Calculation as of: 2026-10-06T17:56:14.865Z.
Quote observation: 2026-10-06T17:55:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 719625f658538d7511a1815ebd8f3969041d2dee7d9c9a78aa46ea1e1d2f6eab
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$302.90M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CapsoVision, Inc. (CV) | $324.92M | N/A | N/A | N/A | N/A |
| Sanara MedTech Inc. (SMTI)vs › | $321.76M | 3.60% | 3.79% | 2.88% | 2.88% |
| Cabaletta Bio, Inc. (CABA)vs › | $321.48M | N/A | N/A | N/A | N/A |
| ClearPoint Neuro, Inc. (CLPT)vs › | $320.59M | N/A | N/A | N/A | N/A |
| Avita Medical Inc. (RCEL)vs › | $319.73M | N/A | N/A | N/A | N/A |
| Agenus Inc. (AGEN)vs › | $318.98M | 12.00% | 6.91% | 6.91% | 10.15% |
| C4 Therapeutics, Inc. (CCCC)vs › | $314.56M | N/A | N/A | N/A | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $302.32M | N/A | 6.62% | 6.62% | 6.62% |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $302.90M | N/A | N/A | N/A | N/A |
| Relmada Therapeutics, Inc. (RLMD)vs › | $349.18M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
